0%

est. 2Y upside i

HealthcareSeries B

Luminai helps automate repetitive manual work away from your mission…

Rank

#2167

Sector

Healthcare AI Automation

Est. Liquidity

~5Y

Data Quality

Data: Low

Luminai has strong potential but lacks disclosed financial data for precise analysis.

Last updated: July 4, 2026

Bull (20%)+100%

Enterprise AI adoption accelerates; revenue reaches $12M by 2028 with 60% growth; multiple expands to 15x. Entry valuation assumed $75M, exit $180M.

Base (55%)+20%

Steady growth to $8M revenue by 2028; multiple compresses to 10x; exit value $80M, slight upside from $75M entry.

Bear (25%)-80%

Sales cycles lengthen; revenue stagnates at $5M; multiple drops to 5x; exit $25M, below $60M liquidation preference; common stock near-zero.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

80%

Total funding $60M vs estimated entry valuation ~$75M implies 80% preference overhang, severely diluting common.

Dilution Risk

low

Recent $38M Series B provides >5 years runway; near-term raise unlikely.

Secondary Liquidity

none

No secondary market observed; exit likely via M&A or IPO in 5+ years.

Engineering — 4 roles

Commerical — 2 roles

Deployments — 2 roles

Operations — 2 roles

Product — 1 role

View all 11 open roles at Luminai →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Luminai's data — designed to show you've done your homework.

  • 1

    “How does Luminai’s AI moat deepen with healthcare data over time?”

  • 2

    “What is the typical sales cycle and ACV for health system deals?”

  • 3

    “What is the equity strike price and what liquidity events are expected?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.